IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1-27 (Cancelled).

Claim 28 (Currently amended): A method for ~~promoting the take of~~ providing a graft ~~in~~ to a mammal in need thereof, the method comprising:

a) ~~taking~~ providing the graft from one or more of the group consisting of a suitable donor, ~~a cell culture and a suitable tissue~~ cultured epidermal cells, acellular dermal matrix, cellular matrix, skin, and mucosa,

b) ~~administering to~~ contacting a non-mineralized tissue recipient bed or lesion with a prophylactically effective amount of an active enamel substance, and

c) placing the graft on ~~said~~ the pre-treated non-mineralized tissue recipient bed or lesion.

Claim 29 (Currently amended): A method according to claim 28, wherein the active enamel substance is applied in an amount of total protein per cm of graft bed area corresponding to ~~from about 0.01 mg/cm^2 to about 20 mg/cm^2, such as~~ from about 0.1 mg/cm^2 to about 15 mg/cm^2.

Claim 30 (Currently amended): A method according to claim 28, wherein the active enamel substance is applied on ~~the site of~~ the recipient bed or lesion before application of the graft described in step c).

Claim 31 (Previously presented): A method according to claim 30, wherein the active enamel substance is applied for a period of up to 72 hours before the application of the graft.

Claim 32 (Previously presented): A method according to claim 28, wherein the graft is a skin graft or mucosal graft.

Claim 33 (Previously presented): A method according to claim 28, wherein the graft is an autogenous skin graft.

Claim 34 (Previously presented): A method according to claim 28, wherein the graft is a full-thickness, split-thickness, composite, seed or mesh graft.

Claim 35 (Previously presented): A method according to claim 28, wherein the graft comprises epidermal cells.

Claims 36-40 (Cancelled).

Claim 41 (Currently amended): A method according to claim 28, wherein the active enamel substance is enamel matrix, ~~enamel matrix derivatives~~, enamel matrix proteins, derivatives thereof, or mixtures thereof.

Claim 42 (Currently amended): A method according to claim 28, wherein the active enamel substance is selected from the group consisting of enamelins, amelogenins, non-amelogenins, proline-rich amelogenins, amelins, ~~and~~ tuftelins, mixtures thereof, and derivatives of said substances.

Claim 43 (Previously presented): A method according to claim 28, wherein the active enamel substance has a molecular weight of up to about 120 kDa as determined by SDS Page electrophoresis.

Claim 44 (Previously presented): A method according to claim 28, wherein the active enamel substance has a molecular weight of up to about 100 kDa as determined by SDS Page electrophoresis.

Claim 45 (Previously presented): A method according to claim 28, wherein the active enamel substance has a molecular weight of up to about 60 kDa as determined by SDS Page electrophoresis.

Claim 46 (Currently amended): A method according to claim 28, wherein the ~~preparation of an active~~ enamel substance contains a mixture of active enamel substances with different molecular weights.

Claim 47 (Currently amended): A method according to claim 28, wherein the preparation of an active enamel substance comprises at least one substance selected from the group consisting of amelogenins, proline-rich non-amelogenins, tuftelins, tuft proteins, serum proteins, salivary proteins, amelin, ameloblastin, sheathlin, mixtures thereof, and derivatives thereof.

Claim 48 (Previously presented): A method according to claim 28, wherein the active enamel substance has a molecular weight of between about 5,000 and about 25,000.

Claim 49 (Previously presented): A method according to claim 28, wherein the major part of the active enamel substance has a molecular weight of about 20 kDa.

Claim 50 (Previously presented): A method according to claim 28, wherein at least a part of the active enamel substance is in the form of aggregates or after application in vivo is capable of forming aggregates.

Claim 51 (Currently amended): A method according to claim ~~28~~ 50, wherein the aggregates have a particle size of from about 20 nm to about 1 µm.

Claim 52 (Previously presented): A method according to claim 28, wherein the protein content of the active enamel substance in the preparation is in a range of from about 0.05% w/w to 100% w/w.

Claim 53 (Previously presented): A method according to claim 28, wherein the protein content of the active enamel substance in the preparation is in a range of from about 30-90% w/w.

Claim 54 (Currently amended): A method according to claim 28, wherein a pharmaceutical or cosmetic composition comprising an active enamel substance and a pharmaceutically acceptable excipient is in step b) administered to ~~a~~ the mammalian recipient bed or lesion.

Claim 55 (Currently amended): A method according to claim 54, wherein the pharmaceutically ~~or cosmetically~~ acceptable excipient is propylene glycol alginate.

Claims 56-65 (Cancelled).